Granulocyte-macrophage colony-stimulating factor autoantibodies: A marker of aggressive Crohn's disease

Inflammatory Bowel Diseases

Volumn 19, Issue 8, 2013, Pages 1671-1680

  Gathungu, Grace ^a   Kim, Mi Ok ^b   Ferguson, John P ^c   Sharma, Yashoda ^c   Zhang, Wei ^c   Ng, Sok Meng E ^c   Bonkowski, Erin ^d   Ning, Kaida ^c   Simms, Lisa A ^e,f   Croft, Anthony R ^f   Stempak, Joanne M ^g   Walker, Nicole ^f   Huang, Ning ^e   Xiao, Yang ^h   Silverberg, Mark S ^g   Trapnell, Bruce ^d   Cho, Judy H ^c   Radford Smith, Graham L ^e,f   Denson, Lee A ^d  

^a STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^e QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^f ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^g MOUNT SINAI HOSPITAL   (Canada)

^h UNIVERSITY OF CINCINNATI   (United States)

Author keywords

Crohn's disease; Granulocyte macrophage colony stimulating factor antibody; Inflammatory bowel disease; Smoking

Indexed keywords

AUTOANTIBODY; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR ANTIBODY;

ADULT; ALLELE; ARTICLE; AUSTRALIA; BLOOD SAMPLING; COHORT ANALYSIS; CONTROLLED STUDY; CROHN DISEASE; DISEASE DURATION; DISEASE MARKER; ENVIRONMENTAL EXPOSURE; FEMALE; GENETIC MARKER; GENETIC RISK; HUMAN; INTESTINE RESECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SMOKING; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AUTOANTIBODIES; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; CONSTRICTION, PATHOLOGIC; CROHN DISEASE; FEMALE; FOLLOW-UP STUDIES; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INFANT; INFANT, NEWBORN; INTESTINAL OBSTRUCTION; MALE; MIDDLE AGED; PROGNOSIS; RISK FACTORS; YOUNG ADULT;

EID: 84884543521     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0b013e318281f506     Document Type: Article

References (45)

1. Cho JH. The genetics and immunopathogenesis of inflammatory bowel disease. Nat Rev Immunol. 2008;8:458-466.
2. Mayer L. Evolving paradigms in the pathogenesis of IBD. J Gastroenterol. 2010;45:9-16.
3. Barrett JC, Hansoul S, Nicolae DL, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet. 2008;40:955-962.
4. Franke A, Balschun T, Karlsen TH, et al. Replication of signals from recent studies of Crohn's disease identifies previously unknown disease loci for ulcerative colitis. Nat Genet. 2008;40:713-715.
5. Silverberg MS, Cho JH, Rioux JD, et al. Ulcerative colitis-risk loci on chromosomes 1p36 and 12q15 found by genome-wide association study. Nat Genet. 2009;41:216-220.
6. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucinerich repeat variants with susceptibility to Crohn's disease. Nature. 2001; 411:599-603.
7. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature. 2001;411: 603-606.
8. Parkes M, Barrett JC, Prescott NJ, et al. Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility. Nat Genet. 2007;39:830-832.
9. Rioux JD, Xavier RJ, Taylor KD, et al. Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. Nat Genet. 2007;39:596-604.
10. Ebert EC, Panja A, Das KM, et al. Patients with inflammatory bowel disease may have a transforming growth factor-beta-, interleukin (IL)-2-or IL-10-deficient state induced by intrinsic neutralizing antibodies. Clin Exp Immunol. 2009;155:65-71.
11. Han X, Uchida K, Jurickova I, et al. Granulocyte-macrophage colonystimulating factor autoantibodies in murine ileitis and progressive ileal Crohn's disease. Gastroenterology. 2009;136:1261-1271; e1-3.
12. Shi Y, Liu CH, Roberts AI, et al. Granulocyte-macrophage colonystimulating factor (GM-CSF) and T-cell responses: what we do and don't know. Cell Res. 2006;16:126-133.
13. Kitamura T, Tanaka N, Watanabe J, et al. Idiopathic pulmonary alveolar proteinosis as an autoimmune disease with neutralizing antibody against granulocyte/macrophage colony-stimulating factor. J Exp Med. 1999;190: 875-880.
14. Schoch OD, Schanz U, Koller M, et al. BAL findings in a patient with pulmonary alveolar proteinosis successfully treated with GM-CSF. Thorax. 2002;57:277-280.
15. Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55:749-753.
16. Fan JB, Chee MS, Gunderson KL. Highly parallel genomic assays. Nat Rev Genet. 2006;7:632-644.
17. Jurinke C, Oeth P, van den Boom D. MALDI-TOF mass spectrometry: a versatile tool for high-performance DNA analysis. Mol Biotechnol. 2004;26:147-164.
18. Uchida K, Nakata K, Trapnell BC, et al. High-affinity autoantibodies specifically eliminate granulocyte-macrophage colony-stimulating factor activity in the lungs of patients with idiopathic pulmonary alveolar proteinosis. Blood. 2004;103:1089-1098.
19. Franke A, McGovern DP, Barrett JC, et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet. 2010;42:1118-1125.
20. Marks DJ, Rahman FZ, Sewell GW, et al. Crohn's disease: an immune deficiency state. Clin Rev Allergy Immunol. 2010;38:20-31.
21. Jung HC, Eckmann L, Yang SK, et al. A distinct array of proinflammatory cytokines is expressed in human colon epithelial cells in response to bacterial invasion. J Clin Invest. 1995;95:55-65.
22. Sennikov SV, Temchura VV, Kozlov VA, et al. The influence of conditioned medium from mouse intestinal epithelial cells on the proliferative activity of crypt cells: role of granulocyte-macrophage colony-stimulating factor. J Gastroenterol. 2002;37:1048-1051.
23. Sainathan SK, Hanna EM, Gong Q, et al. Granulocyte macrophage colonystimulating factor ameliorates DSS-induced experimental colitis. Inflamm Bowel Dis. 2008;14:88-99.
24. Bernasconi E, Favre L, Maillard MH, et al. Granulocyte-macrophage colony-stimulating factor elicits bone marrow-derived cells that promote efficient colonic mucosal healing. Inflamm Bowel Dis. 2010;16: 428-441.
25. Korzenik JR, Dieckgraefe BK, Valentine JF, et al. Sargramostim for active Crohn's disease. N Engl J Med. 2005;352:2193-2201.
26. Takazoe M, Matsui T, Motoya S, et al. Sargramostim in patients with Crohn's disease: results of a phase 1-2 study. J Gastroenterol. 2009;44: 535-543.
27. Valentine JF, Fedorak RN, Feagan B, et al. Steroid-sparing properties of sargramostim in patients with corticosteroid-dependent Crohn's disease: a randomised, double-blind, placebo-controlled, phase 2 study. Gut. 2009; 58:1354-1362.
28. Kelsen JR, Rosh J, Heyman M, et al. Phase I trial of sargramostim in pediatric Crohn's disease. Inflamm Bowel Dis. 2010;16:1203-1208.
29. Magno P, Jimenez CE, Ortiz Z, et al. Recombinant human granulocytemacrophage colony stimulating factor (sargramostim) as an alternative therapy for fistulizing Crohn's disease. Puerto Rico Health Sci J. 2010; 29:60-65.
30. Wong AC, Lee SD. Long-term therapy with sargramostim in a patient with Crohn's disease. Inflamm Bowel Dis. 2011;17:1447-1448.
31. Lawrance IC, Batman B, Gearry RB, et al. Smoking cessation following the diagnosis of Crohn's disease still reduces the rates of surgery and complicated disease. Gastroenterology. 2011;140:S429-S429.
32. Van Kemseke C, Belaiche J, Steeman C, et al. Negative association between smoking and anti-Saccharomyces cerevisiae antibodies in Crohn's disease. Acta Gastro-Enterologica Belg. 2003;66:1-6.
33. Vander Cruyssen B, Peeters H, Hoffman IEA, et al. CARD15 polymorphisms are associated with anti-Saccharomyces cerevisiae antibodies in Caucasian Crohn's disease patients. Clin Exp Immunol. 2005;140: 354-359.
34. Arnson Y, Shoenfeld Y, Amital H. Effects of tobacco smoke on immunity, inflammation and autoimmunity. J Autoimmun. 2010;34:J258-J265.
35. Inoue Y, Trapnell BC, Tazawa R, et al. Characteristics of a large cohort of patients with autoimmune pulmonary alveolar proteinosis in Japan. Am J Respir Crit Care Med. 2008;177:752-762.
36. Lindberg E, Jarnerot G, Huitfeldt B. Smoking in Crohn's disease: effect on localisation and clinical course. Gut. 1992;33:779-782.
37. Mahid SS, Minor KS, Stevens PL, et al. The role of smoking in Crohn's disease as defined by clinical variables. Dig Dis Sci. 2007; 52: 2897-2903.
38. Sutherland LR, Ramcharan S, Bryant H, et al. Effect of cigarette smoking on recurrence of Crohn's disease. Gastroenterology. 1990;98:1123-1128.
39. Cosnes J, Carbonnel F, Carrat F, et al. Effects of current and former cigarette smoking on the clinical course of Crohn's disease. Aliment Pharmacol Ther. 1999;13:1403-1411.
40. Louis E, Michel V, Hugot JP, et al. Early development of stricturing or penetrating pattern in Crohn's disease is influenced by disease location, number of flares, and smoking but not by NOD2/CARD15 genotype. Gut. 2003;52:552-557.
41. Picco MF, Bayless TM. Tobacco consumption and disease duration are associated with fistulizing and stricturing behaviors in the first 8 years of Crohn's disease. Am J Gastroenterol. 2003;98:363-368.
42. Aldhous MC, Drummond HE, Anderson N, et al. Does cigarette smoking influence the phenotype of Crohn's disease? Analysis using the Montreal classification. Am J Gastroenterol. 2007;102:577-588.
43. Samson CM, Jurickova I, Molden E, et al. Granulocyte-macrophage colony stimulating factor blockade promotes ccr9(+) lymphocyte expansion in Nod2 deficient mice. Inflamm Bowel Dis. 2011; 17:2443-2455.
44. Rivera-Nieves J, Ho J, Bamias G, et al. Antibody blockade of CCL25/CCR9 ameliorates early but not late chronic murine ileitis. Gastroenterology. 2006; 131:1518-1529.
45. Walters MJ, Wang Y, Lai N, et al. Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease. J Pharmacol Exp Ther. 2010;335:61-69.